“With the Union Budget 2026 allocation crossing the ₹1 lakh crore mark for the first time in the healthcare industry, we are seeing a structural shift from a social utility to a high-growth asset class.The ₹10,000 crore Biopharma Shakti programme and 1,000 accredited clinical trial sites act as significant de-risking mechanisms for investors. By upgrading NIPERs and strengthening the CDSCO, the government is creating a predictable regulatory pathway that encourages long-term capital deployment in deep science.
This industrial depth is balanced by immediate market resilience through customs exemptions on 36 life-saving drugs. Furthermore, the training of one lakh allied professionals addresses the talent shortage that typically limits how fast healthcare startups can scale operations.
To fully leverage this, we must recognize that the BioPharma Strategy for Health Advancement through Knowledge, Technology, and Innovation will strengthen India’s digital ecosystem in healthcare. Consequently, the investment focus can now shift to the invisible layers of the health stack, which includes backing backend health data infrastructure and AI-driven diagnostics. This transitions India to a unified, patient-first digital economy, offering massive scalability for startups serving both domestic and global needs.”
- Advertisement -
